Ten-year trends in lipid management among patients after myocardial infarction in South Korea

• Published in: PloS one Vol. 19; no. 10; p. e0304710
• Main Authors: Oh, Seok, Cho, Kyung Hoon, Kim, Min Chul, Sim, Doo Sun, Hong, Young Joon, Kim, Ju Han, Ahn, Youngkeun, Lee, Sang Yeub, Shin, Min-Ho, Kim, Weon, Jeong, Myung Ho
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 03.10.2024; Public Library of Science (PLoS)
• Subjects: Aged; Biology and Life Sciences; Blood lipids; Cardiac patients; Cardiology; Cardiovascular disease; Care and treatment; Cholesterol; Cholesterol, LDL - blood; Clinical outcomes; Coronary vessels; Demographics; Drugs; Dyslipidemia; Dyslipidemias - drug therapy; Dyslipidemias - epidemiology; Evaluation; Ezetimibe - therapeutic use; Female; Heart attack; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Ischemia; Lipids; Low density lipoprotein; Low density lipoproteins; Male; Management; Medical research; Medicine and Health Sciences; Medicine, Experimental; Metabolic disorders; Middle Aged; Mortality; Myocardial infarction; Myocardial Infarction - drug therapy; Myocardial Infarction - epidemiology; Patient monitoring; Patient outcomes; Population studies; Prescribing; Prescriptions; Prevalence; Republic of Korea - epidemiology; Review boards; Risk Factors; Risk reduction; Statins; Trends; Vein & artery diseases; Republic of Korea; South Korea; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0304710

Dyslipidemia is an important risk factor for acute myocardial infarction. However, real-world data on its prevalence and lipid management trends for Korean patients with acute myocardial infarction are limited. This study aimed to determine the 10-year temporal trends in dyslipidemia prevalence and lipid management in this patient population. The study used a merged database of two nationwide observational cohorts (2011-2020) that included 26,751 participants. The primary endpoints were the achievement rates of the (1) absolute low-density lipoprotein cholesterol (LDL-C) target of <70 mg/dL (<1.8 mmol/L), (2) relative LDL-C target reduction of >50% from the baseline, (3) absolute or relative LDL-C target (American target), and (4) both absolute and relative LDL-C targets (European target). The dyslipidemia prevalence increased from 11.1% to 17.1%, whereas the statin prescription rate increased from 92.9% to 97.0% from 2011 to 2020. The rate of high-intensity statin use increased from 12.80% in 2012 to 69.30% in 2020. The rate of ezetimibe use increased from 4.50% in 2016 to 22.50% in 2020. The high-intensity statin and ezetimibe prescription rates (0.20% to 9.30% from 2016 to 2020) increased gradually. The absolute and relative LDL-C target achievement rates increased from 41.4% and 20.8% in 2012 to 62.5% and 39.5% in 2019, respectively. The American (45.7% in 2012 to 68.6% in 2019) and European (16.5% in 2012 to 33.8% in 2019) target achievement rates also increased. The adoption of lipid management guidelines in clinical practice has improved. However, continued efforts are needed to reduce the risk of recurrent ischemic events.